Assoc. Prof. Dr. Ant Uzay
Assoc. Prof. Dr. Ant Uzay is a hematology specialist at Acıbadem Atakent Hospital in İstanbul, working in the Hematology Department and the adult Bone Marrow Transplant Unit. He treats leukemias, multiple myeloma, lymphomas, anemia and bleeding disorders, and is involved in bone marrow transplantation.
- 26+ Years of Experience
- 25 Scientific Publications
- BMT Adult Transplant Unit
- NEJM REACH3 Co-Author
About
Assoc. Prof. Dr. Ant Uzay is a hematology specialist at Acıbadem Atakent Hospital in İstanbul. He works in the Hematology Department and in the adult Bone Marrow Transplant Unit, where his practice covers acute and chronic leukemias, multiple myeloma, lymphomas, anemias, bleeding disorders and other bone marrow diseases, as well as bone marrow transplantation.
He graduated from Trakya University Faculty of Medicine in 2000 and completed his training in Internal Medicine (2005) and Hematology (2009) at Marmara University Faculty of Medicine. He served as a hematology specialist at GATA Haydarpaşa Training and Research Hospital between 2009 and 2010.
His research centres on stem cell transplantation: conditioning regimens, graft-versus-host disease and infections after transplant. He was a co-author of the phase III REACH3 study of ruxolitinib in chronic graft-versus-host disease, published in The New England Journal of Medicine. He is a member of the European Hematology Association and the Turkish Society of Hematology, and consults in Turkish and English.
Areas of Expertise
Adult hematology, with a focus on blood cancers and bone marrow transplantation.
Bone Marrow Transplantation
Allogeneic and autologous stem cell transplantation in the adult unit — from assessing whether a patient is a candidate to donor choice, conditioning and recovery.
Acute Myeloid Leukemia
Diagnosis with genetic and molecular risk assessment, induction and consolidation treatment, and the decision on transplantation in first remission.
Acute Lymphoblastic Leukemia
Treatment of adult ALL, including Philadelphia-positive disease, with chemotherapy, targeted agents and transplantation where indicated.
Chronic Myeloid Leukemia
Long-term management with tyrosine kinase inhibitors, molecular monitoring of response, and the questions of switching or stopping treatment.
Hairy Cell Leukemia
Diagnosis and treatment of this rare, slow-growing leukemia, which usually responds well and can remain in remission for many years.
Multiple Myeloma
Treatment with modern combinations including proteasome inhibitors, stem cell collection and autologous transplantation, and care of kidney and bone complications.
Lymphomas
Hodgkin and non-Hodgkin lymphomas, including relapsed and refractory disease, salvage treatment and consolidation with transplantation.
Graft-versus-Host Disease
Prevention and treatment of acute and chronic GVHD after allogeneic transplant, including steroid-refractory disease — the subject of the REACH3 study.
Anemia and Iron Deficiency
Finding the cause of anemia before treating it, from iron, B12 and folate deficiency to anemias that come from the bone marrow itself.
Immune Thrombocytopenia
Assessment of a low platelet count, separating ITP from other causes, and treatment matched to bleeding risk rather than the number alone.
Von Willebrand Disease
Diagnosis and management of the most common inherited bleeding disorder, including planning ahead of surgery, dental work and childbirth.
Bone Marrow Diseases
Evaluation of bone marrow disorders with blood tests, bone marrow aspiration and biopsy, and the genetic tests that guide treatment.
Education
Specialty Training in Hematology
Marmara University Faculty of Medicine
Specialty Training in Internal Medicine
Marmara University Faculty of Medicine
Doctor of Medicine (MD)
Trakya University Faculty of Medicine
Career
Hematology Specialist, Hematology Department and Adult Bone Marrow Transplant Unit
Acıbadem Healthcare Services — Acıbadem Atakent Hospital, İstanbul
Hematology Specialist (Medical Second Lieutenant)
GATA Haydarpaşa Training and Research Hospital, İstanbul
transplant unit
Blood cancers and bone marrow transplantation
Most of Dr. Uzay's work sits where a blood cancer meets the question of transplantation. For acute leukemia, high-risk lymphoma or multiple myeloma, the first decisions are about the right treatment now; the next ones are about whether and when a transplant would add to it, which donor, and which conditioning regimen a given patient can tolerate. After transplant the focus moves to recovery: preventing and treating graft-versus-host disease and the infections that follow a period of low immunity. Alongside this sits the rest of adult hematology — anemia and iron deficiency, immune thrombocytopenia and bleeding disorders such as Von Willebrand disease — where careful diagnosis is often the most important step.
- Allogeneic and autologous bone marrow transplantation
- Acute myeloid and acute lymphoblastic leukemia
- Chronic myeloid leukemia
- Multiple myeloma and lymphomas
- Graft-versus-host disease after transplant
- Anemia, thrombocytopenia and bleeding disorders
Achievements and Awards
REACH3 in The New England Journal of Medicine
Co-author of the phase III study that established ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease.
REACH3 Final Analysis
Co-author of the three-year final analysis of the REACH3 study, published in the Journal of Clinical Oncology.
Treosulfan Conditioning
First author of a single-centre study showing treosulfan as a safe alternative to busulfan for conditioning in adult transplant patients.
BEGEV in Hodgkin Lymphoma
First author of a real-life study of BEGEV salvage treatment in heavily pretreated, platinum-resistant Hodgkin lymphoma.
Publications and Research
Selected peer-reviewed articles on stem cell transplantation, graft-versus-host disease, lymphoma and multiple myeloma.
-
N Engl J Med 2021
Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease
-
J Clin Oncol 2025
Ruxolitinib in corticosteroid-refractory or -dependent chronic GVHD: 3-year final analysis of the phase III REACH3 study
-
Cancer Medicine 2024
Treosulfan is a safe and effective alternative to busulfan for conditioning in adult allogeneic HSCT patients
-
Indian J Hematol Blood Transfus 2025
BEGEV is an effective therapy for heavily pretreated and platinum-resistant relapsed/refractory Hodgkin lymphoma
-
J Infect Chemother 2023
Daily low dose intravesical cidofovir for BK virus associated hemorrhagic cystitis after allogeneic stem cell transplantation
-
Front Public Health 2026
Time-adjusted direct medical costs of moderate-to-severe chronic graft-versus-host disease in Türkiye
-
Hematol Oncol 2023
Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: real-world data
-
Hematology 2011
Bortezomib in patients with renal impairment
Articles on Blood Diseases
Plain explanations of the conditions Dr. Uzay treats — what a diagnosis means, which options exist, and when a transplant becomes part of the plan.
Frequently Asked Questions
Which blood disorders does Dr. Uzay treat?
He treats acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), multiple myeloma, lymphomas and other bone marrow diseases. He also manages anemia, including iron deficiency anemia, immune thrombocytopenia (ITP) and Von Willebrand disease, and is involved in bone marrow transplantation for adult patients.
Does Dr. Uzay perform bone marrow transplantation?
Yes. He works in the adult Bone Marrow Transplant Unit at Acıbadem Atakent Hospital and is involved in bone marrow transplantation. Whether transplantation is suitable for a particular patient is decided individually after a full review of the diagnosis, disease course and previous treatments.
What is the difference between an autologous and an allogeneic transplant?
In an autologous transplant the patient's own stem cells are collected, stored and given back after high-dose treatment; it is used mainly in multiple myeloma and some lymphomas. In an allogeneic transplant the stem cells come from a donor — a sibling, an unrelated volunteer or a half-matched family member — and the new immune system also helps control the disease. Which one fits depends on the diagnosis and its risk.
What is graft-versus-host disease?
After an allogeneic transplant, immune cells from the donor can react against the patient's own tissues, most often the skin, mouth, eyes, liver and gut. Medication is given to prevent it, and when it does occur it is graded and treated; for chronic GVHD that does not respond to steroids, ruxolitinib — studied in the REACH3 trial Dr. Uzay co-authored — is one of the established options.
Where does Dr. Uzay see patients?
At Acıbadem Atakent Hospital in İstanbul, in the Hematology Department and the adult Bone Marrow Transplant Unit. The international patient team arranges appointments and organises the hospital visit.
What should I send for a case review?
Recent blood counts and laboratory results, bone marrow and pathology reports, flow cytometry and genetic test results if available, imaging reports such as CT, PET-CT or MRI, and a summary of previous treatment and response. The international patient team coordinates the collection of these documents.
Is a video consultation possible before travelling?
Yes. Video consultation is available for international patients who wish to discuss their diagnosis and treatment options with Dr. Uzay before travelling to İstanbul, including the question of whether transplantation should be considered.
In which languages can I have my consultation?
Dr. Uzay consults in Turkish and English. For patients who speak other languages, interpreters can be arranged through the international patient team.
Appointment Request
Contact Us
Share your reports and results for an initial assessment, or request an appointment at Acıbadem Atakent Hospital. The international patient team usually responds within 2 hours.
Hospital
Acıbadem Atakent Hospital
Halkalı Merkez Mah., Turgut Özal Bulvarı No: 16
34303 Küçükçekmece / İstanbul
Details
Response within 2 hours
Support in 20+ languages
Free, no-obligation initial guidance